Prof. Xiaoli Lan: Pioneer in Advanced PET/CT Molecular Imaging & PRRT Radionuclide Therapy at Wuhan Union Hospital

1. Clinical & Academic Leadership: Pioneering Molecular Theranostics in China

Professor Xiaoli Lan is an internationally recognized leader in nuclear oncology and molecular imaging, currently serving as Director of the Department of Nuclear Medicine at Wuhan Union Hospital, affiliated with Tongji Medical College of Huazhong University of Science and Technology (HUST). Professor Lan has stood at the vanguard of the global shift from passive anatomical imaging to active molecular theranostics—the seamless fusion of precision molecular diagnostics with targeted radionuclide destruction of cancer cells.

Wuhan Union Hospital’s nuclear medicine center is designated as a National Key Specialty, equipped with state-of-the-art medical cyclotrons, ultra-high-sensitivity digital PET/CT systems, and dedicated radiopharmaceutical synthesis laboratories, making it a pivotal national hub for complex oncologic evaluations.

2. Primary Clinical Focus & Theranostic Capabilities

Professor Xiaoli Lan's clinical practice specializes in tertiary-level molecular staging and innovative targeted radionuclide therapies for conditions that confound conventional diagnostic modalities:

• Peptide Receptor Radionuclide Therapy (PRRT): Delivering personalized beta- and alpha-emitting radiopharmaceutical infusions (such as Lutetium-177 DOTATATE) for advanced, inoperable, or metastatic neuroendocrine tumors (NETs) of the gastroenteropancreatic system.
• Targeted Radioligand Theranostics (PSMA & FAPI): Utilizing Gallium-68 and Fluorine-18 labeled Prostate-Specific Membrane Antigen (PSMA) and Fibroblast Activation Protein Inhibitor (FAPI) tracers to detect microscopic recurrent prostate cancer and stromal-rich gastrointestinal/gynecologic tumors.
• Whole-Body Systemic PET/CT Staging for Occult Cancers: Pinpointing primary occult lesions in patients presenting with metastatic carcinoma of unknown primary (CUP) and resolving indeterminate solitary pulmonary or hepatic nodules.
• Multi-Parametric Immunotherapy Response Prediction: Utilizing specialized radiotracers to visualize tumor immune checkpoint expression (such as PD-L1 and CD8+ T-cell infiltration) in vivo, predicting therapeutic response prior to costly checkpoint inhibitor administration.

3. Landmark Scientific Research: JNM & Novel Molecular Probes

Professor Lan’s laboratory is celebrated worldwide for developing and translating proprietary radio-conjugate tracers, published extensively in the Journal of Nuclear Medicine (JNM) and the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI):

• Novel Molecular Imaging Probes for Tumor Microenvironments: Engineered and clinically validated proprietary radiolabeled peptides and nanobodies that selectively bind to neoangiogenic markers and tumor stroma, offering tenfold higher contrast ratios than standard 18F-FDG in low-glycolytic malignancies.
• PET Metrics Predicting Immunotherapy Efficacy: Delineated multi-parametric PET quantification models integrating metabolic tumor volume (MTV), total lesion glycolysis (TLG), and tracer kinetics to predict hyperprogression versus durable remission in lung cancer and melanoma patients receiving immunotherapy.
• National Guidelines Leadership: Serving on the drafting committees for national clinical guidelines governing PET/CT oncology reporting standards, neuroendocrine tumor PRRT consensus protocols, and radiopharmaceutical safety regulations across China.

4. Transformative Innovations in Bedside Practice

Professor Lan has brought the clinical philosophy of "treating what you see, and seeing what you treat" to life for patients facing complex malignancies:

• Solving Carcinoma of Unknown Primary (CUP): Combining novel molecular probes with high-resolution digital PET/CT, Professor Lan's unit consistently identifies primary tumor sites in over 70% of referred CUP cases where conventional CT, MRI, and endoscopy failed, enabling targeted curative therapies instead of empiric palliative chemotherapy.
• Dosimetry-Guided PRRT Personalization: Implementing individualized internal radiation dosimetry based on pre-therapeutic imaging, maximizing the radiation dose delivered directly into neuroendocrine metastatic lesions while rigorously shielding renal and bone marrow reserves.
• Real-Time Functional Monitoring of Treatment Resistance: Employing receptor-specific imaging during active targeted therapy to identify emerging molecular clones that have down-regulated target receptors, guiding immediate strategic adjustments.

5. Benchmark Clinical Case Scenarios

Professor Lan’s clinical unit routinely resolves complex oncologic dilemmas referred from across China and abroad:

• Case Scenario 1 (Successful PRRT in Metastatic Neuroendocrine Tumor): A patient with progressive, widespread liver and retroperitoneal metastases from an inoperable pancreatic neuroendocrine tumor (G2) failed somatostatin analogue therapy. Professor Lan performed 68Ga-DOTATATE PET/CT confirming intense universal receptor avidity, followed by 4 customized cycles of 177Lu-DOTATATE PRRT. Follow-up imaging demonstrated over 65% objective tumor volume reduction, complete resolution of carcinoid symptoms, and normalization of chromogranin A.
• Case Scenario 2 (Detection of Occult Micrometastases via FAPI PET/CT): A patient with post-surgical gastric adenocarcinoma presented with rising CEA levels despite negative conventional contrast-enhanced CT and 18F-FDG PET/CT scans. Professor Lan directed a 68Ga-FAPI PET/CT scan, cleanly revealing multiple 3 mm peritoneal seeding implants along the mesentery. This early detection allowed prompt intraperitoneal hyperthermic chemotherapy (HIPEC) before gross ascites developed.

6. Accessing Professor Xiaoli Lan for International Patients

International patients seeking expert PET/CT second opinions, novel tracer molecular scans, or PRRT radionuclide therapy can access Professor Xiaoli Lan through structured medical coordination:

1. Imaging & Medical Dossier Assembly: Complete oncologic treatment history, official pathology and immunohistochemistry reports, digital DICOM files of previous CT, MRI, or PET scans, and recent renal function panels (GFR, creatinine) and complete blood counts.
2. Pre-Screening & Molecular Avidity Evaluation: Rapid review to verify histological diagnosis, evaluate performance status, and determine whether receptor-targeted imaging (e.g., DOTATATE, PSMA, or FAPI) is clinically indicated.
3. Physician Review & Theranostic Protocol Design: Authorized submission to Professor Lan’s specialized molecular imaging tumor board for diagnostic review or comprehensive PRRT treatment cycle planning.
4. Concierge & Inpatient Coordination: Dedicated support encompassing medical visa documentation, cyclotron radiopharmaceutical synthesis scheduling, specialized lead-shielded inpatient suite reservations, and bilingual bedside medical liaison.

7. Inquire & Request a Clinical Assessment

China Medical Concierge - Shanghai (CMCS) is an independent health management and medical concierge service. We connect international patients and expatriates with leading specialists and premier national academic medical centers across China.

To inquire about case reviews, PET/CT scan coordination, or PRRT radionuclide therapy with Professor Xiaoli Lan’s team, please reach out directly through our official channels: